The Innovative Health Initiative (IHI) GUIDE.MRD Consortium partners met for the 2nd Annual General Assembly hosted by the coordinating institution at the Universitätsklinikum Hamburg Eppendorf (UKE), from 29-30 April 2024 and organized with the support of Innovation Acta S.r.l. (INN-ACTA).
After a warm welcome to the beautiful city of Hamburg by the Project Coordinator Klaus Pantel (UKE) and the Project Leader, Bristol Myers Squibb (BMS) represented by Luigi Ravagnan, the progress on all work packages was presented by the work package (WP) leads and co-leads.
- WP1 “Project Management and Coordination”: Riccardo Bertini (INN-ACTA) and Klaus Pantel (UKE);
- WP2 “Development of ctDNA Reference Materials and analytical benchmarking of ctDNA diagnostics for MRD assessment”: Ellen Heitzer (MUG);
- WP3 “GUIDE.MRD-01-through-03 clinical studies on CRC, PDAC and NSCLC”: Claus Lindbjerg Andersen (AUH), Matthias Löhr (KI), Jeroen Hiltermann (UMCG);
- WP4 “Data management, governance, statistical and AI analysis”: Núria Malats (CNIO);
- WP5 “Communication, dissemination and exploitation”: Daniel J. Smit (UKE);
- WP6 “Stakeholder engagement”: Lidewij Eva Vat (The Synergist), Bianca Cucos (INOMED)) and Ana Martins (DiCE) on behalf of the GUIDE.MRD patient advisory board (PAB);
- WP7 “Ethics”: (Daniel J. Smit (UKE).
Moreover, a fruitful plenum discussion with all participants on current challenges and mitigation strategies as well as the next steps within the consortium was held.
Over 30 participants from the 25 partners engaged in very productive discussions on the results reached by the consortium in the first 12 months.
We would like to thank all partners involved!
